By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



245 First Street - 18th Floor
Suite 1806
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-444-8416 Fax: 617- 444-8405

Genfit is a biopharmaceutical company, listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111) with headquarters in Lille, France and a US subsidiary in Cambridge, Massachusetts.

Through its world-renowned scientific expertise, particularly in the field of nuclear receptors, Genfit’s research efforts are focused on the discovery and development of new treatments mainly in the growing therapeutic areas of Cardiometabolic and Neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer’s. Genfit uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health problems and their unmet medical needs.

Genfit has an original business model built on both proprietary internal programs and a strong track record of partner-supported programs and collaborations. This strategy allows the company to efficiently manage the risks associated with the internal programs, and at the same time build value for its shareholders. Genfit, on its own or in collaboration with its major pharmaceutical partners, has thus created a rich and diversified pipeline of drug candidates in pre-clinical and clinical development, as well as a broad intellectual property portfolio.

Genfit’s strong portfolio of therapeutic products, tools, and clinical biomarkers, together with its scientific expertise, have made the Company into a European biotechnology leader.

Parc Eurasanté – Lille Metropole
885 Avenue Eugene Avinee
59120 Loos
Tel : +33 (0)3 2016 4000
Fax : +33 (0)3 2016 4001

Key Statistics

Ownership: Public

Web Site: GENFIT
Employees: 125 (Scientists: 100)
Symbol: ALGFT

Company News
GENFIT (ALGFT) Announces Elafibranor Presentations And Presidential Plenary At The 2015 AASLD Annual Meeting 10/2/2015 9:46:04 AM
GENFIT (ALGFT): Half-Year Results For 2015 9/25/2015 1:52:44 PM
GENFIT (ALGFT) Announces Positive Results From Proprietary Nash Biomarker Program 9/15/2015 9:39:03 AM
GENFIT (ALGFT): Outcome Of The Annual General Meeting Of June 3, 2015 6/3/2015 1:16:54 PM
GENFIT (ALGFT): Elafibranor Accepted As The Generic Name For Gft505 By The WHO 6/2/2015 9:37:07 AM
GENFIT (ALGFT): Ordinary General Shareholders’ Meeting Of June 3, 2015 – Availability Of Preparatory Documents 5/7/2015 1:50:12 PM
GENFIT (ALGFT) Announces Its Turnover And Cash Situation As Of March 31, 2015 5/7/2015 10:51:41 AM
GENFIT (ALGFT): New Proof Of Efficacy Of Gft505 In Nash And Positive Expert Opinion 4/24/2015 8:45:43 AM
GENFIT (ALGFT): Annual Results For 2014 4/3/2015 1:16:25 PM
GENFIT (ALGFT)'s GFT505 Misses Target in Phase IIB But Hopes to Proceed to Phase III 3/27/2015 7:05:21 AM